Therapeutic opportunities and targets in childhood leukemia

被引：4

作者：

Ford A.M. ^{[1
]}

Martínez-Ramírez Á. ^{[2
]}

机构：

[1] Section of Haemato-Oncology, Institute of Cancer Research, Sutton

[2] Molecular Cytogenetics Laboratory, MD Anderson International España, 28055 Madrid, C/Gómez Hemans

来源：

Clinical and Translational Oncology | 2006年 / 8卷 / 8期

关键词：

Acute lymphoblastic leukemia; Chromosome translocations; Fusion genes; Immunotherapy; Leukemic stem cell; Monoclonal antibodies;

D O I：

10.1007/s12094-006-0061-5

中图分类号：

学科分类号：

摘要：

Childhood leukemia is a common pediatric cancer in the developed world, the disease is biologically diverse and there is much discussion as to its causal mechanisms. Acute lymphoblastic leukemia (ALL) is the most common subtype and infants with ALL have a greatly increased risk of treatment failure. There are molecular and biological properties of leukemic cells that determine treatment outcome; these can usually be attributed to distinct genetic abnormalities that alter the normal proliferative and survival signals of hematopoietic cells. Experimental evidence for the existence of leukemic stem cells (LSC) has been obtained, and it is presumed that these cells arise from mutations in normal hematopoetic stem cells or progenitor cells, and they are difficult to eradicate. LSC seem to be surprisingly different from their normal counterparts and therefore are obvious new targets for drug therapy. Therapeutic concepts using monoclonal antibodies have substantially improved response rates in patients with malignant lymphomas and are currently being evaluated in other types of cancer. © FESEO 2006.

引用

页码：560 / 565

页数：5

共 42 条

[1]

Libura J., Slater D.J., Felix C.A., Richardson C., Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion, Blood, 105, 5, pp. 2124-2131, (2005)

[2]

Huret J.L., Dessen P., Bernheim A., An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners, Leukemia, 15, pp. 987-989, (2001)

[3]

Ford A.M., Bennett C.A., Price C.M., Bruin M.C., Van Wering E.R., Greaves M., Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia, Proc Natl Acad Sci USA, 95, 8, pp. 4584-4588, (1998)

[4]

Ford A.M., Fasching K., Panzer-Grumayer E.R., Koenig M., Haas O.A., Greaves M.F., Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes, Blood, 98, 3, pp. 558-564, (2001)

[5]

Greaves M., In utero origins of childhood leukaemia, Early Hum Dev, 81, 1, pp. 123-129, (2005)

[6]

Armstrong S.A., Golub T.R., Korsmeyer S.J., MLL-rearranged leukemias: Insights from gene expression profiling, Semin Hematol, 40, 4, pp. 268-273, (2003)

[7]

Armstrong S.A., Kung A.L., Mabon M.E., Et al., Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification, Cancer Cell, 3, 2, pp. 173-183, (2003)

[8]

Stirewalt D.L., Radich J.P., The role of FLT3 in haematopoietic malignancies, Nat Rev Cancer, 3, 9, pp. 650-665, (2003)

[9]

Smith B.D., Bao T., Karp J.E., New concepts in the treatment of acute myeloid malignancies: Selected pathways for targeted therapy, J Biol Regul Homeost Agents, 19, 1-2, pp. 23-32, (2005)

[10]

Stam R.W., den Boer M.L., Schneider P., Et al., Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia, Blood, 106, 7, pp. 2484-2490, (2005)

← 1 2 3 4 5 →